The State of the Science in Biotherapeutics Research and Development
Antibody research in response to the COVID-19 pandemic has crash-tested new discovery technologies and caused the industry to find new ways of conducting discovery and development faster and more efficiently. With this as a foundation, the PEGS Engineering
Stream examines the state of the science in biologics R&D, including smarter and higher throughput screening methods, new technologies to accelerate and optimize antibody engineering and the increasing role of machine learning in discovery and
engineering. The Stream also explores developments in therapeutic antibodies for neurodegeneration, autoimmunity, cardiovascular disease and infectious diseases. Plan to join these essential tracks and see why PEGS has become the industry’s
must-attend event in biotherapeutics R&D.
Conferences Include:
May 2-3
Display of Biologics
May 3-4
Engineering Antibodies
May 5-6
Machine Learning Approaches for Protein Engineering
Keynote Presentations:
Protein Structure Prediction in a Post-AlphaFold2 World
Mohammed AlQuraishi, PhD, Assistant Professor, Systems Biology, Columbia University
How Structure-Based Machine Learning Can Drive the Development of Biotherapeutics
Charlotte M. Deane, PhD, Professor of Structural Bioinformatics, Statistics, University of Oxford
From Alpha to Epsilon: A Global Consortium Study to Define Variant Resistant Epitopes on SARS-CoV-2 Spike
Kathryn M. Hastie, PhD, Instructor, La Jolla Institute for Immunology
Applications of Nanobodies to Laboratory Diagnosis
Serge Muyldermans, PhD, Professor & Group Leader, Cellular & Molecular Immunology Lab, Vrije University Brussels